2023-09-28 15:00:00
Specifically, it is regarding the data from the phase III study Eradicate with the antibiotic ceftobiprole, as Basilea announced on Thursday.
The study examined ceftobiprole for the treatment of Staphylococcus aureus bacteremia (SAB), a bacterial bloodstream infection caused by Staphylococcus aureus, in adult patients.
Eradicate was the largest approval study carried out for SAB to date, Basilea also reports. Importantly, ceftobiprole demonstrated comparable clinical benefit to daptomycin, a standard antibiotic for the treatment of SAH.
High medical need
“There is a great need for new therapies for patients in this area,” study leader Thomas Holland from the Duke University School of Medicine is quoted as saying in the statement. “No new antibiotic has been approved for the treatment of Staphylococcusaureus bacteremia in over 15 years.”
Basilea applied for US approval of ceftobiprole in August. As Basilea wrote at the time, Staphylococcus aureus bacteremia is a common bloodstream infection with an estimated 120,000 cases per year in the United States, often with severe disease and high mortality.
On the SIX, Basilea shares temporarily rose 0.24 percent to CHF 41.10.
Allschwil (awp)
1695934433
#Basilea #shares #premiums #Basilea #publishes #data #antibiotic #ceftobiprole #renowned #journal
